Company news
Allarity Therapeutics, Inc. news in 2025
Allarity Therapeutics, Inc.'s news releases, calls and decks from 2025, newest first.
Allarity Therapeutics Issues 2025 End of Year CEO Letter to Shareholders
December 31, 2025
Allarity Therapeutics Provides Third Quarter 2025 Financial Results and Provides Business Updates
November 14, 2025
Allarity Therapeutics Presents New Phase 2 Clinical Data for Stenoparib/2X-121 Showing Landmark Median Overall Survival Has Now Surpassed 25 Months
September 22, 2025
Allarity Therapeutics CEO to Present at Biomarkers & Precision Medicine 2025
September 17, 2025
Allarity Therapeutics Granted FDA Fast Track Designation for Stenoparib for the Treatment of Advanced Ovarian Cancer
August 26, 2025
Allarity Therapeutics Provides Second Quarter 2025 Update, Highlighting Clinical Progress, IP Expansion, and New Partnerships
August 15, 2025
Corporate Presentation 2025 Q2
July 24, 2025
Allarity Therapeutics Announces New Licensing and Laboratory Services Agreement to Expand DRP® Platform Utilization
July 15, 2025
Allarity Therapeutics Announces Appointment of Jeff Ervin as Chief Financial Officer
July 7, 2025
Allarity Therapeutics Receives Australian Patent Acceptance Notice for Stenoparib DRP® Companion Diagnostic
June 30, 2025
Allarity Therapeutics Announces Dosing of Second Patient in New Phase 2 Trial of Stenoparib in Advanced Ovarian Cancer
June 27, 2025
Allarity Therapeutics Announces Changes to Board of Directors
June 11, 2025
Allarity Therapeutics Announces Research Collaboration with Indiana Biosciences Research Institute to Further Advance Understanding of Stenoparib’s Unique, Dual Therapeutic Mechanism of Action
June 4, 2025
Allarity Therapeutics Announces First Patient Enrolled in New Phase 2 Clinical Trial Protocol of Stenoparib in Advanced Ovarian Cancer
June 2, 2025
Allarity Therapeutics Announces Participation in Pharma Partnering Summit US
May 12, 2025
Allarity Therapeutics Provides First Quarter 2025 Update, Highlighting Continued Stenoparib Benefit and Upcoming Trial Enrollment
May 9, 2025
Allarity Therapeutics Presents Novel Drug Response Predictor—DRP®—for Daratumumab in Multiple Myeloma at AACR 2025
April 24, 2025
Allarity Therapeutics Reports Full Year 2024 Financial Results and Provides a Business Update
March 31, 2025
Allarity Therapeutics Launches Comprehensive Effort to Combat Potential Illegal Naked Short Selling of Its Shares
March 24, 2025
Allarity Therapeutics Announces Presentation of Phase 2 Clinical Data from Ongoing Trial in Advanced Ovarian Cancer Patients at the 2025 Annual Meeting for the Society of Gynecologic Oncology
March 17, 2025
Allarity Therapeutics Announces Final Settlement with the U.S. Securities and Exchange Commission
March 13, 2025
Allarity Therapeutics Announces Phase 2 Trial of Stenoparib in Combination with Temozolomide for Recurrent Small Cell Lung Cancer Fully Funded by the US Veterans Administration
March 6, 2025
Allarity Therapeutics Announces Board Authorization of $5 Million Share Repurchase Program
March 3, 2025
Allarity Therapeutics Announces Dismissal of Securities Class Action Lawsuit
February 26, 2025
Allarity Therapeutics to Begin Enrollment for New Phase 2 Protocol to Advance Stenoparib Toward FDA Approval in Advanced Ovarian Cancer Patients
February 24, 2025
Allarity Therapeutics Announces Expansion of Phase 2 Clinical Trial to Accelerate Development of Stenoparib in Advanced Ovarian Cancer
February 5, 2025
Allarity Therapeutics Announces Filing of Form 8-K Regarding Settlement Agreement in Principle with SEC
January 29, 2025
Decks in 2025
- Investor Presentation (May 2025)
Investor deck · 24 slides · May 2025